In conclusion, compared with placebo, SGLT2 inhibitors significantly reduced HHF and KSCO and increased KCCQ total score in patients without T2DM with HF or CKD, without increasing the risks of volume depletion, fracture, amputation, major hypoglycemia, and diabetic ketoacidosis. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.